FLT3 and acute myeloid leukemia: Analysis of the 20 APL patients separately from the non‐APL AML cases discerned two signatures solely based on their proteomic profiles and, thus, irrespective of mutant FLT3 status or cytogenetic aberrations that yielded prognostic information.